Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Case 16: A 75-Year-Old Man With Macroglossia and Hypercalcemia.
Kim J, Kim N, Jeon Y, Kim TY, Kim TJ, Kwon HS, Park CS, Baek KH. Kim J, et al. Among authors: kim ty, kim tj, kim n. J Korean Med Sci. 2023 Nov 13;38(44):e374. doi: 10.3346/jkms.2023.38.e374. J Korean Med Sci. 2023. PMID: 37967882 Free PMC article. No abstract available.
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML).
Park S, Kwag D, Kim TY, Lee JH, Lee JY, Min GJ, Park SS, Yahng SA, Jeon YW, Shin SH, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Lee JW, Kim HJ. Park S, et al. Among authors: kim yj, kim hj, kim ty. Ther Adv Hematol. 2022 Mar 23;13:20406207221081637. doi: 10.1177/20406207221081637. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35340720 Free PMC article.
Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification.
Kim TY, Park S, Kwag D, Lee JH, Lee J, Min GJ, Park SS, Jeon YW, Shin SH, Yahng SA, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Lee JW, Kim HJ. Kim TY, et al. Among authors: kim yj, kim hj. Cancers (Basel). 2022 Jun 29;14(13):3199. doi: 10.3390/cancers14133199. Cancers (Basel). 2022. PMID: 35804971 Free PMC article.
Long-term treatment outcome of Castleman's disease: A real-world experience.
Min GJ, Jeon YW, Kim TY, Kwag DH, Lee JH, Lee JY, Park SS, Park S, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Lee JW, Cho SG. Min GJ, et al. Among authors: kim yj, kim hj, kim ty. Front Oncol. 2022 Aug 5;12:974770. doi: 10.3389/fonc.2022.974770. eCollection 2022. Front Oncol. 2022. PMID: 35992883 Free PMC article.
Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients.
Kim TY, Kwag D, Lee JH, Lee J, Min GJ, Park SS, Park S, Jeon YW, Yoon JH, Shin SH, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Cho SG, Lee JW, Lee JM, Kim M, Lee SE. Kim TY, et al. Among authors: kim yj, kim hj, kim m. Cancers (Basel). 2022 Sep 16;14(18):4485. doi: 10.3390/cancers14184485. Cancers (Basel). 2022. PMID: 36139644 Free PMC article.
Efficacy of ex vivo purging with CD34+ selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients.
Jeon Y, Kim TY, Min GJ, Park SS, Park S, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, Cho SG. Jeon Y, et al. Among authors: kim yj, kim hj, kim ty. Cytotherapy. 2023 Dec;25(12):1307-1316. doi: 10.1016/j.jcyt.2023.07.005. Epub 2023 Aug 4. Cytotherapy. 2023. PMID: 37542512 Free article.
2,670 results